Literature DB >> 12130519

Decreased susceptibility of leukemic cells with PIG-A mutation to natural killer cells in vitro.

Shoichi Nagakura1, Sonoko Ishihara, Daniel E Dunn, Jun-ichi Nishimura, Tatsuya Kawaguchi, Kentaro Horikawa, Michihiro Hidaka, Tadashi Kagimoto, Nozomu Eto, Hiroaki Mitsuya, Taroh Kinoshita, Neal S Young, Hideki Nakakuma.   

Abstract

The cloning of the PIG-A gene has facilitated the unraveling of the complex pathophysiology of paroxysmal nocturnal hemoglobinuria (PNH). Of current major concern is the mechanism by which a PNH clone expands. Many reports have suggested that an immune mechanism operates to cause bone marrow failure in some patients with PNH, aplastic anemia, and myelodysplastic syndromes. Because blood cells of PNH phenotype are often found in patients with these marrow diseases, one hypothesis is that the PNH clone escapes immune attack, producing a survival advantage by immunoselection. To test this hypothesis, we examined the sensitivity of blood cells, with or without PIG-A mutations, to killing by natural killer (NK) cells, using 51Cr-release assay in vitro. To both peripheral blood and cultured NK cells, PIG-A mutant cells prepared from myeloid and lymphoid leukemic cell lines were less susceptible than their control counterparts (reverted from the mutant cells by transfection with a PIG-A cDNA). NK activity was completely abolished with concanamycin A and by calcium chelation, indicating that killing was perforin-dependent. There were no differences in major histocompatibility (MHC) class I expression or sensitivity to either purified perforin or to interleukin-2-activated NK cells between PIG-A mutant and control cells. From these results, we infer that PIG-A mutant cells lack molecules needed for NK activation or to trigger perforin-mediated killing. Our experiments suggest that PIG-A mutations confer a relative survival advantage to a PNH clone, contributing to selective expansion of these cells in the setting of marrow injury by cytotoxic lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12130519     DOI: 10.1182/blood.v100.3.1031

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

Review 1.  Pathogenesis of selective expansion of PNH clones.

Authors:  Hideki Nakakuma; Tatsuya Kawaguchi
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

Review 2.  New insights into molecular pathogenesis of bone marrow failure in paroxysmal nocturnal hemoglobinuria.

Authors:  Tatsuya Kawaguchi; Hideki Nakakuma
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

3.  Paroxysmal nocturnal hemoglobinuria.

Authors:  Mitsuhiro Omine; Taroh Kinoshita; Hideki Nakakuma; Jaroslaw P Maciejewski; Charles J Parker; Gérard Socié
Journal:  Int J Hematol       Date:  2005-12       Impact factor: 2.490

Review 4.  Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia.

Authors:  Amy E DeZern; Robert A Brodsky
Journal:  Hematol Oncol Clin North Am       Date:  2015-03-07       Impact factor: 3.722

5.  Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria.

Authors:  Lova Sun; Daria V Babushok
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

Review 6.  Immune pathogenesis of paroxysmal nocturnal hemoglobinuria.

Authors:  Ramon Tiu; Jaroslaw Maciejewski
Journal:  Int J Hematol       Date:  2006-08       Impact factor: 2.490

Review 7.  Paroxysmal nocturnal haemoglobinuria.

Authors:  Anita Hill; Amy E DeZern; Taroh Kinoshita; Robert A Brodsky
Journal:  Nat Rev Dis Primers       Date:  2017-05-18       Impact factor: 52.329

8.  Paroxysmal nocturnal hemoglobinuria with copy number-neutral 6pLOH in GPI (+) but not in GPI (-) granulocytes.

Authors:  Yasutaka Ueda; Jun-ichi Nishimura; Yoshiko Murakami; Sachiko Kajigaya; Taroh Kinoshita; Yuzuru Kanakura; Neal S Young
Journal:  Eur J Haematol       Date:  2014-01-30       Impact factor: 2.997

9.  Two cases of acute myeloblastic leukemia evolving from aplastic anemia.

Authors:  Akihiko Taguchi; Takayuki Tominaga; Yoshitaka Nakamori; Mutsuko Miyazaki; Kenji Shinohara
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

10.  Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents.

Authors:  Antonio M Risitano; Bruno Rotoli
Journal:  Biologics       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.